Zepbound Questions Answered: Cost, Doses, Savings, Sleep Apnea

Zepbound (tirzepatide) is a once-weekly injection made by Eli Lilly. It is FDA-approved for two uses: long-term weight reduction in adults with obesity or overweight plus a weight-related condition, and moderate-to-severe obstructive sleep apnea in adults with obesity ^[1]. It was first approved on November 8, 2023, and the sleep apnea indication was added on December 20, 2024 ^[15][3].

Without insurance, Lilly’s self-pay prices are $299 per month for the 2.5 mg dose and $399 for the 5 mg dose, and $449 per month for 7.5 mg and higher doses as long as each refill is completed within 45 days of the previous delivery ^[6][11]. The list price of $499 to $1,086.37 per fill is a wholesale figure, not what most patients pay ^[5]. Below are factual answers to the questions people ask most often.

What is Zepbound?

Zepbound is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist, injected under the skin once a week ^[1]. It is used together with a reduced-calorie diet and increased physical activity for two approved uses: reducing excess body weight and keeping it off long term in adults with obesity, or adults with overweight who have at least one weight-related comorbid condition; and treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity ^[1].

The FDA approved Zepbound on November 8, 2023 for weight management ^[15]. On December 20, 2024, the FDA approved it for moderate-to-severe OSA in adults with obesity, which Lilly described as the first and only prescription medicine for that condition ^[3][15].

Is Zepbound the same as Mounjaro?

Both drugs contain the same active ingredient, tirzepatide. Mounjaro was approved in May 2022 and Zepbound in November 2023 ^[23]. In the United States, Mounjaro’s approved use is improving glycemic control in adults with type 2 diabetes; outside the US, the Mounjaro brand is approved in some countries for obesity or overweight with a weight-related comorbid condition ^[16].

Mounjaro and Zepbound are the only FDA-approved tirzepatide products, and Lilly’s exclusivity on tirzepatide extends to 2027 ^[23]. The label states that Zepbound should not be combined with other tirzepatide-containing products or with any GLP-1 receptor agonist ^[1].

Is Zepbound stronger than Wegovy?

In one head-to-head trial, people taking tirzepatide lost more weight than people taking semaglutide, the active ingredient in Wegovy. SURMOUNT-5 was a phase 3b, open-label trial funded by Lilly that enrolled 751 adults with obesity but without type 2 diabetes and ran for 72 weeks ^[4]. Participants received the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg) once weekly ^[4].

At week 72, average weight change was -20.2% with tirzepatide versus -13.7% with semaglutide, and waist circumference fell 18.4 cm versus 13.0 cm ^[4]. The most common adverse events in both groups were gastrointestinal, mostly mild to moderate, and occurred mainly during dose escalation ^[4].

How much does Zepbound cost without insurance?

Lilly’s list price, also called the wholesale acquisition cost (WAC), is $499 to $1,086.37 per fill. WAC is the price Lilly sells to wholesalers, not what patients pay at the pharmacy ^[5]. A month is defined as 28 days ^[5].

For self-pay patients, Lilly offers direct pricing on the single-dose vial and the KwikPen through LillyDirect, and the KwikPen self-pay pricing is also available at major pharmacies nationwide ^[6][8]. TrumpRx lists Zepbound at $299 per month against an original price of $1,087, though drugs cannot be bought directly on TrumpRx ^[21][12].

Dose	Self-pay price (45-day refill rule applies only to 7.5 mg and above)	KwikPen regular price (outside 45-day window)
2.5 mg	$299/month	$299/month
5 mg	$399/month	$399/month
7.5 mg	$449/month	$499/month
10 mg	$449/month	$699/month
12.5 mg	$449/month	$699/month
15 mg	$449/month	$699/month

Sources: LillyDirect and Zepbound savings pages ^[6][11].

These prices have moved over time. On February 25, 2025, Lilly launched 7.5 mg and 10 mg single-dose vials at $499 through the Self Pay Journey Program and cut the 2.5 mg vial to $349 and the 5 mg vial to $499 ^[10]. On December 1, 2025, vial prices dropped to $299 (2.5 mg), $399 (5 mg), and $449 (7.5 to 15 mg) ^[7]. The FDA approved the KwikPen on January 20, 2026, and on March 16, 2026, KwikPen self-pay pricing became available at major pharmacies nationwide in addition to LillyDirect ^[24][15][8].

Why was I charged more than $449?

The $449 price for the 7.5, 10, 12.5, and 15 mg doses applies to the first purchase and to refills completed within 45 days of the previous delivery ^[11][6]. If a refill is completed more than 45 days after the previous delivery, the purchase offer no longer applies and regular KwikPen prices take over: $499 for 7.5 mg and $699 for 10 mg, 12.5 mg, and 15 mg ^[6][11]. The Self Pay Journey Program works the same way, applying to the first fill and refills within 45 days of prior delivery ^[7].

Who qualifies for the Zepbound savings card?

There are separate offers depending on insurance and product. Adults with commercial drug insurance that covers the Zepbound single-dose pen may pay as little as $25 for a one-, two-, or three-month fill ^[11][5]. Adults with commercial insurance that does not cover the single-dose pen may pay as low as $499 for a one-month fill ^[11].

The KwikPen Self-Pay Savings Card, launched March 16, 2026, is available to all patients including those without insurance, but it applies only to the KwikPen, not to single-dose vials or the single-dose pen ^[8]. People enrolled in government-funded programs are excluded, including Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, VA, DoD, TRICARE, and state prescription drug assistance programs ^[11]. Savings are subject to monthly and annual limits, and Lilly may amend or terminate the card terms at any time ^[5].

Does Medicare cover Zepbound?

Starting July 1, 2026, Medicare is running a short-term demonstration called the Medicare GLP-1 Bridge that runs through December 31, 2027 and provides eligible Part D beneficiaries access to certain GLP-1 drugs for a $50 copay ^[13][12]. Zepbound is covered under the Bridge as the KwikPen only; the program does not cover single-dose Zepbound vials or pens ^[12].

The Part D deductible does not apply, no part of the $50 copay counts toward true out-of-pocket (TrOOP) costs, and there is no low-income subsidy for Bridge claims ^[13]. Eligibility requires being 18 or older and meeting one of these when starting GLP-1 therapy: BMI of 35 or higher; BMI of 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension, or stage 3a or higher chronic kidney disease; or BMI of 27 or higher with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease ^[12].

People with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease are not eligible for the Bridge, but their Part D plan might cover GLP-1 drugs for those conditions ^[12]. A Bridge prior authorization is valid, including refills and dose changes, through December 31, 2027 unless the GLP-1 is changed, and the provider must certify the drug is part of a lifestyle program ^[12]. The American Academy of Sleep Medicine notes that some Medicare plans with drug coverage may cover Zepbound for treating OSA but not for weight loss alone ^[20].

What happened with CVS Caremark coverage?

On July 1, 2025, CVS Caremark stopped covering Zepbound on its most common formulary template, which represents between 25 and 30 million people; Wegovy remained covered ^[14]. Many insurers also require prior authorization before covering Zepbound ^[20]. The American Academy of Sleep Medicine suggests that prescribers can improve approval odds by submitting a one-page letter of medical necessity and documenting comorbid conditions, prior therapies, and BMI trends ^[20].

What is the difference between the KwikPen and the vial?

Zepbound comes in three presentations, and every approved presentation is a subcutaneous injection ^[15]. The single-dose pen and single-dose vial contain 0.5 mL and come in six strengths from 2.5 mg to 15 mg ^[1][15]. The KwikPen and the multi-dose vial contain 2.4 mL and deliver four weekly doses of 0.6 mL each ^[1][24].

The single-dose vial is available only through LillyDirect for self-pay patients, and a separate needle and syringe purchase is required ^[6]. The KwikPen requires a pen needle purchase, and the label warns never to share a KwikPen between patients, even with a new needle, because of the risk of transmitting blood-borne pathogens ^[6][1]. Zepbound purchases are HSA/FSA eligible, though eligibility varies by plan ^[6].

How should Zepbound be stored?

All presentations should be stored in the refrigerator between 36°F and 46°F ^[1]. A single-dose pen or single-dose vial can be kept at room temperature up to 86°F for a total of 21 days, after which it must be discarded ^[1]. A KwikPen or multi-dose vial may be kept in the refrigerator or at room temperature up to 86°F, and must be discarded after a total of 30 days at room temperature, 30 days after first use, or after four weekly doses, whichever comes first ^[1].

Is 2.5 mg a maintenance dose?

No. The 2.5 mg dose is for treatment initiation and is not approved as a maintenance dosage ^[1]. The recommended starting dosage is 2.5 mg once weekly for 4 weeks, after which the dose can be increased in 2.5 mg increments after at least 4 weeks on the current dose ^[1]. The label’s recommended maintenance dosages are 5 mg, 10 mg, or 15 mg once weekly for weight reduction and long-term maintenance, and 10 mg or 15 mg once weekly for OSA, with a maximum of 15 mg ^[1]. Dose selection is a matter for a prescriber, who considers treatment response and tolerability ^[1].

How much weight do people lose on Zepbound?

In the label’s Study 1 (SURMOUNT-1), a 72-week trial of 2,539 adults with obesity or overweight plus a weight-related condition but without type 2 diabetes, average weight change at 72 weeks was -15.0% on 5 mg, -19.5% on 10 mg, and -20.9% on 15 mg, versus -3.1% on placebo ^[1]. In Study 2, which enrolled adults with type 2 diabetes, average weight change was -12.8% on 10 mg and -14.7% on 15 mg, versus -3.2% on placebo ^[1]. These are averages at 72 weeks, and every arm, including placebo, received a lifestyle intervention with a reduced-calorie diet and increased physical activity ^[1].

A DXA substudy of 160 SURMOUNT-1 participants found that about 75% of the weight lost with tirzepatide was fat mass and about 25% was lean mass at week 72 ^[18].

What happens if the dose is lowered or treatment stops?

Two late-phase trials reported in May 2026 looked at maintenance after higher-dose treatment. SURMOUNT-MAINTAIN enrolled 441 participants who took a maximum tolerated dose of Zepbound (10 mg or 15 mg) for 60 weeks, then continued at that dose, dropped to 5 mg, or switched to placebo for 52 more weeks; results were published in The Lancet ^[16]. Those who stayed on the maximum tolerated dose preserved all of their prior weight loss on average, while those who dropped to 5 mg kept all but 5.6 kg ^[16]. In ATTAIN-MAINTAIN, participants who switched from Zepbound to Foundayo, a once-daily oral GLP-1, kept all but 5.0 kg of their previous weight loss on average ^[16].

The American Academy of Sleep Medicine points to the SURMOUNT-4 trial as support for continuing pharmacotherapy to prevent weight regain, and notes that discontinuing tirzepatide may affect any reductions in apnea-hypopnea index and improvements in OSA severity experienced while on the drug ^[20]. Any decision about changing or stopping a dose belongs with a prescriber.

What are the side effects and warnings?

The most common side effects reported in at least 5% of patients are nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity, eructation, hair loss, and gastroesophageal reflux ^[1].

The label carries a boxed warning that tirzepatide causes thyroid C-cell tumors in rats and that Zepbound is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 ^[1]. Other warnings include severe gastrointestinal adverse reactions, acute kidney injury from volume depletion, gallbladder disease, pancreatitis, hypersensitivity, hypoglycemia when used with insulin or an insulin secretagogue, and pulmonary aspiration during anesthesia or deep sedation ^[1].

On February 25, 2026, the FDA approved a label update that removed the suicidal ideation and behavior subsection at the FDA’s request of January 13, 2026, and added intestinal obstruction and severe constipation, including fecal impaction, to the postmarketing experience section ^[17][15].

Can Zepbound be used for sleep apnea?

Yes, it is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity ^[1]. The approval rests on SURMOUNT-OSA, two 52-week double-blind trials that randomized 469 participants, one in people not on PAP therapy and one in people planning to stay on PAP; results were published in the New England Journal of Medicine on June 21, 2024 ^[19][3].

Average apnea-hypopnea index (AHI) fell 25.3 events per hour with tirzepatide versus 5.3 with placebo in the trial without PAP, and 29.3 versus 5.5 in the trial with PAP, from baseline averages of 51.5 and 49.5 events per hour ^[19]. After one year, 42% of adults on Zepbound and 50% of those on Zepbound with PAP therapy had remission or mild, non-symptomatic OSA, compared with 16% and 14% on placebo ^[3]. The American Academy of Sleep Medicine describes tirzepatide as an adjunct, not a replacement for CPAP, and says CPAP should not be stopped without reassessment ^[20].

Where can you get Zepbound online?

With a valid prescription, Zepbound is available through LillyDirect, with insurance or self-pay and with home delivery or pickup, at major retail pharmacies, and through Amazon Pharmacy, which offers cash-pay pricing starting at $299 per month for the 2.5 mg KwikPen starter dose ^[6][8][9].

What about compounded tirzepatide?

Compounded drugs are not FDA-approved, and the FDA does not review their safety, effectiveness, or quality before they reach patients ^[23]. The FDA determined the tirzepatide shortage resolved on October 2, 2024, and confirmed that decision on December 19, 2024; the Fifth Circuit affirmed the FDA’s action on August 27, 2026 ^[23]. FDA enforcement discretion for outsourcing facilities compounding tirzepatide ended March 19, 2025, after the 503A period had already ended, and as of April 2026 tirzepatide does not appear on the FDA shortage list or the 503B bulks list ^[22].

Sources

1. National Library of Medicine DailyMed. ZEPBOUND (tirzepatide) injection, solution.
2. US Food and Drug Administration. New Drug Application 217806 review document (PDF).
3. Eli Lilly and Company. FDA approves Zepbound (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity. December 20, 2024.
4. New England Journal of Medicine. Tirzepatide as compared with semaglutide for the treatment of obesity.
5. Eli Lilly and Company. Zepbound cost information with or without insurance.
6. Eli Lilly and Company. Authentic Zepbound (tirzepatide) shipped to you. LillyDirect.
7. Eli Lilly and Company. Lilly lowers the price of Zepbound (tirzepatide) single-dose vials. December 1, 2025.
8. Eli Lilly and Company. Media statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect. March 16, 2026.
9. Business Wire. Amazon Pharmacy expands access to Eli Lilly’s Zepbound KwikPen for weight management. March 9, 2026.
10. Eli Lilly and Company. Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients. February 25, 2025.
11. Eli Lilly and Company. Savings and insurance options. Zepbound (tirzepatide).
12. Medicare.gov. Weight loss drugs.
13. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge.
14. CNN. Major insurance changes are coming to GLP-1 drugs for weight loss. Here’s how that could affect patients. July 1, 2025.
15. US Food and Drug Administration. Drugs@FDA: New Drug Application 217806, Eli Lilly and Co.
16. Eli Lilly and Company. Lilly’s Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials. May 12, 2026.
17. US Food and Drug Administration. Supplement approval letter, NDA 217806/S-042, Zepbound (tirzepatide) injection.
18. Diabetes, Obesity and Metabolism. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. 2025.
19. New England Journal of Medicine. Tirzepatide for the treatment of obstructive sleep apnea and obesity.
20. American Academy of Sleep Medicine. What clinicians should know about prescribing tirzepatide for sleep apnea.
21. TrumpRx. TrumpRx: lower prices on medications.
22. US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.
23. US Court of Appeals for the Fifth Circuit. Outsourcing Facilities Association v. FDA, No. 25-10600, unpublished opinion. August 27, 2026.
24. US Food and Drug Administration. Supplement approval letter, NDA 217806/S-002, Zepbound KwikPen (tirzepatide) injection.